Bracco Diagnostics

Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium sulfate) for oral suspension, which is indicated for modified barium swallow (MBS) studies. The contrast agent is used to detect and assess the type and severity of swallowing disorders also known as dysphagia.

Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company based in Oxford, U.K. Subject to customary closing conditions, completion of the transaction is expected in the third quarter of this calendar year.

Physicians and technologists at Children’s Hospital of Philadelphia (CHOP) will be able to conduct research and education on the use of contrast ultrasound thanks to a $300,000 grant from Bracco Diagnostics Inc. USA. Contrast ultrasound is a relatively new technology that was only approved for use in pediatric patients in 2016. CHOP is among the first pediatric hospitals to use this technology in the U.S.

August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of ...

The volume of computed tomography (CT) imaging exams continues to grow in the United States,^[2] adding pressure to hospitals and radiology departments to control costs while meeting demand. In the CT suite, productivity and workflow can be impacted in several ways, but a new syringe-less, multi-dose multi-patient power injector is making waves at healthcare facilities with its efficiency-improving performance.